{"id":"targeted-synthetic-dmard-class","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1201467","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The drug's mechanism of action involves the selective inhibition of a specific molecular target, which leads to a reduction in inflammation and an improvement in symptoms associated with autoimmune diseases. This targeted approach allows for a more precise modulation of the immune response, reducing the risk of adverse effects associated with broader immunosuppressive therapies.","oneSentence":"This targeted synthetic DMARD class drug works by selectively inhibiting a specific molecular target to modulate the immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:28.465Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"}]},"trialDetails":[{"nctId":"NCT04692493","phase":"PHASE3","title":"RA-PRO PRAGMATIC TRIAL","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Rheumatoid Arthritis","enrollment":924}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"targeted synthetic DMARD class","genericName":"targeted synthetic DMARD class","companyName":"University of Alabama at Birmingham","companyId":"university-of-alabama-at-birmingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This targeted synthetic DMARD class drug works by selectively inhibiting a specific molecular target to modulate the immune response. Used for Rheumatoid arthritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}